DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Merck - 1 molnupiravir - 1 Theo Sanderson - 1 Francis Crick - 1 Covid - 1 Merck's molnupiravir - 1 Molnupiravir - 1
Top related locs:
U.S London
Top related orgs:
Francis - 1 Francis Crick Institute - 1 Twitter - 1 Merck - 1 U.S . Food - 1 Drug Administration - 1 FDA - 1

Search resuls for: "Merck's molnupiravir"


3 mentions found


☆ Merck Covid drug linked to virus mutations that can spread between people, new study says
  + stars: | 2023-09-25 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
A new study released Monday said Merck 's widely used antiviral Covid pill can cause mutations in the virus that occasionally spread to other people, raising questions about whether the drug has the potential to accelerate Covid's evolution. Molnupiravir works by causing mutations in Covid's genetic information, which weakens or destroys the virus and reduces the amount of Covid in the body. Researchers in the U.S. and U.K. specifically analyzed 15 million Covid genomes to see which mutations had occurred and when. Based on data at the time, a spokesperson for Merck said it didn't believe molnupiravir was likely to contribute to Covid mutations. The new study comes as Covid once again gains a stronger foothold in the U.S., primarily driven by newer strains of the virus.
Persons: Merck, molnupiravir, Theo Sanderson, Francis Crick, Covid, Merck's molnupiravir, Molnupiravir Organizations: Francis, Francis Crick Institute, Twitter, Merck, U.S . Food, Drug Administration, FDA Locations: U.S, London
☆ Merck revenue falls after dramatic drop in sales of Covid antiviral treatment
  + stars: | 2023-04-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Merck on Thursday reported first-quarter revenue that fell 9% from the same period a year ago largely due to a steep drop in sales of its Covid antiviral treatment molnupiravir. Sales of molnupiravir plunged to $392 million during the period, down 88% from the $3.2 billion reported in the first quarter of 2022. Merck said the decrease is primarily the result of lower sales in the U.S., U.K., Japan and Australia. The company reported total revenue of $14.5 billion during the quarter, down nearly $1.5 billion from the same period a year ago. But Merck's pharmaceutical unit saw higher sales of the blockbuster antibody treatment Keytruda, which increased 20% to $5.8 billion during the quarter.
☆ Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
  + stars: | 2022-11-16 | by ( Maggie Fick | ) www.reuters.com   time to read: +3 min
The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. The recommendations are a draft, NICE said, and until final guidance is published, access to COVID-19 medicines will continue as is. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (GILD.O) hospital-administered antiviral remdesivir are effective at treating COVID-19. It also recommended against three other COVID treatments, including GSK (GSK.L) and partner Vir Biotechnology's (VIR.O) sotrovimab, an antibody therapy that the World Health Organization recommended against in September. One expert said that some of the COVID treatments NICE recommended against are an important part of the British government's current strategy.
0 next >>
Total: 3